We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Guido
Franzoso
g.franzoso@imperial.ac.uk
Paola
Arboretto
p.arboretto@imperial.ac.uk
Prof
Guido
Franzoso
g.franzoso@imperial.ac.uk
Jessica
Cornice
j.cornice@imperial.ac.uk
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Multiple myeloma is an incurable cancer of the bone marrow. The primary objective of this study is to establish the efficacy and specificity of new anti-cancer agents in cultured cells from multiple myeloma patients. Its secondary objective is to develop a new biomarker to predict patient outcome and therapy response to inform the design of future clinical trials.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
1. – Patients who have not been diagnosed with one of the following monoclonal gammophathies, according to the criteria established by the International Myeloma Working Group (IMWG) (R. Kyle & S.V. Rajkumar, Leukemia 2009, 23: 39): i. Monoclonal gammopathy of undetermined significance (MGUS) OR Monoclonal gammopathy, unattributed/unassociated (MG[u]) ii. Asymptomatic (smouldering) myeloma (SMM) iii. Symptomatic multiple myeloma (MM) iv. Nonsecretory multiple myeloma v. Solitary plasmacytoma of bone vi. Extramedullary plasmacytoma vi. Extramedullary plasmacytoma (EMP) vii. Multiple solitary plasmacytomas (+/recurrent) viii. Plasma cell leukaemia (PCL) 2. – Patients meeting the inclusion criteria listed in A171, with any other clinical condition which is detrimental to the research project 3. – Patients meeting the inclusion criteria listed in A171 who are pregnant 4. – Patients meeting the inclusion criteria listed in A171, with any other clinical condition, which may expose them to risks higher than normal during the procedures required by the study 5. – Healthy volunteers meeting the inclusion criteria listed in A171, with a clinical condition which is detrimental to the research project 6. – Healthy volunteers meeting the inclusion criteria listed in A171 who are pregnant 7. – Patients meeting the inclusion criteria listed in A171, with a clinical condition, which may expose them to risks higher than normal during the procedures required by the study
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Jessica
Cornice
j.cornice@imperial.ac.uk
Paola
Arboretto
p.arboretto@imperial.ac.uk
Prof
Guido
Franzoso
g.franzoso@imperial.ac.uk
Prof
Guido
Franzoso
g.franzoso@imperial.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 11552
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
